Guide

What to consider when building a channel strategy for a rare disease product

A checklist for biopharma companies

Evaluating channel strategy options for a rare disease product is an essential element of commercialization. Biopharma companies should ask themselves these five questions to ensure their novel therapy reaches the right patients at the right time.

Enter your information below to download the checklist. 

Pardot Form

Related resources

Article

Tips for partnering with health systems: A critical step for CGT commercialization
World Courier team member presents at  a large LED digital display

Webinar

Navigating the healthcare policy landscape: Key insights for managed care and the life sciences industry
people working around a table

Article

Building revenue with mature products in a time of market flux

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.